Clear Cell Renal Cell Carcinoma Clinical Trials

21 studies are recruiting for clear cell renal cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma

   This is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma (ccRCC). The primar…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research site, Omaha, Nebraska

   Run by

   PeptiDream Inc.

   See if you can join NCT07688187 on ClinicalTrials.gov

2. Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

   This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other parts of the body). The study will look at the safety of the…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Mayo Clinic Building- Phoenix, Phoenix, Arizona

   Locations

   162 in total

   Run by

   Pfizer

   See if you can join NCT07227415 on ClinicalTrials.gov

3. Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

   This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell cancer that has not spread from where it first started to other areas of the body (non-metastatic). The current standard treatment for patients…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University Cancer Center LAO, New Haven, Connecticut

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07516366 on ClinicalTrials.gov

4. Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

   This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Banner University Medical Center - Tucson, Tucson, Arizona

   Locations

   425 in total

   Run by

   Alliance for Clinical Trials in Oncology

   See if you can join NCT06661720 on ClinicalTrials.gov

5. A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

   The purpose of this study is to evaluate the safety and tolerability of: * casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and * casdatifan monotherapy and casdatifan in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Birmingham, Alabama

   Locations

   25 in total

   Run by

   Arcus Biosciences, Inc.

   See if you can join NCT05536141 on ClinicalTrials.gov

6. Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

   To learn if belzutifan alone, pembrolizumab alone, or belzutifan and pembrolizumab in combination given before a total or partial nephrectomy (surgery to remove all or part of a kidney) can help to control locally advanced ccRCC.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07187778 on ClinicalTrials.gov

7. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

8. Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study

   The goal of our study is to explore how treatments affect the bone immune microenvironment and determine the best treatment options for patients with metastatic kidney cancer to the bone. This could prevent skeletal complications and improve patient outcomes.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07187869 on ClinicalTrials.gov

9. Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

   The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Xencor Investigative Site, Phoenix, Arizona

   Locations

   26 in total

   Run by

   Xencor, Inc.

   See if you can join NCT05433142 on ClinicalTrials.gov

10. Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

    The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 initially as a monother…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEO-811 Los Angeles Site, Duarte, California

    Locations

    12 in total

    Run by

    Neomorph, Inc

    See if you can join NCT07300241 on ClinicalTrials.gov

11. Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

    To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05663710 on ClinicalTrials.gov

12. Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

    There are 2 parts to this clinical research study: Part 1 (Dose Escalation) and Part 2 (Dose Expansion). The goal of Part 1 is to find the recommended dose of LNK001 in patients with advanced or metastatic ccRCC. The goal of Part 2 is to learn if the recommended dose of LNK001 found in Part 1 can h…

    Stage

    Phase 1

    Ages

    18 to 70

    Site

    UT MD Anderson, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07564232 on ClinicalTrials.gov

13. Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

    This is a single-institution, phase 2 trial of zanzalintinib plus investigator-choice bone-strengthening agent in patients with metastatic renal cell carcinoma (RCC) with bone metastases whose disease has advanced on 1-3 prior lines of therapy, including at least one immune oncology-based (IO) ther…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Kelly Fitzgerald, MD

    See if you can join NCT07043608 on ClinicalTrials.gov

14. An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

    This phase II trial compares the safety and effectiveness of 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) compared to contrast-enhanced CT after surgery in detecting clear cell renal cell cancer that has come back (recurrent). For some patients, the risk of recurrence a…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

    Run by

    Jonsson Comprehensive Cancer Center

    See if you can join NCT06447103 on ClinicalTrials.gov

15. Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

    This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return of disease (recurrence) after surgery for patients with renal cell cancer. Pembrolizumab is an immune checkpoint inhibitor. Immunotherapy wi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope Medical Center, Duarte, California

    Locations

    2 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT07037004 on ClinicalTrials.gov

16. Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

    To learn if belzutifan can help to control the disease in patients with metastatic RCC who are considered candidates for active surveillance and have not undergone previous systemic treatment. The safety of belzutifan in this patient population will also be studied.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    MD Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07023432 on ClinicalTrials.gov

17. Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

    The study population for this Phase 2 study will include men and women ≥ 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycl…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California San Diego, La Jolla, California

    Locations

    4 in total

    Run by

    Karie Runcie

    See if you can join NCT06863311 on ClinicalTrials.gov

18. Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

    The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

    Run by

    University of Oklahoma

    See if you can join NCT07223541 on ClinicalTrials.gov

19. [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

    This is an exploratory study to assess [18F]PT2385 Positron Emission Tomography/Computed Tomography (PET/CT) in patients with renal cell carcinoma (RCC). This is an open-label, nontherapeutic trial. The main objective is to correlate hypoxia-inducible factor-2alpha (HIF2α) levels as determined by a…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Southwestern Medical Center, Dallas, Texas

    Run by

    Orhan Kemal Oz

    See if you can join NCT04989959 on ClinicalTrials.gov

20. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Michigan Hospitals, Ann Arbor, Michigan

    Locations

    5 in total

    Run by

    Novelty Nobility, Inc.

    See if you can join NCT06805825 on ClinicalTrials.gov

21. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sharp Memorial Hospital, San Diego, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov